INDICATIONS AND USAGE

Although sildenafil, vardenafil, and tadalafil all work by inhibiting PDE5, tadalafil's pharmacologic distinction is its longer half-life (17.5 hours),[20] compared to sildenafil and vardenafil, which are both 4–5 hours.

[21] This translates to a longer duration of action, which is partly responsible for "The Weekend Pill" nickname. Furthermore, the longer half-life is the basis for tadalafil's daily therapeutic use in treating pulmonary arterial hypertension.

• Cialis was part of a class of drugs known as PDE5 inhibitors.
• These drugs revolutionized the treatment of erectile dysfunction.
• Lilly invested heavily in development and patent protection for Cialis.
• The medication is generally safe when used as prescribed.
• Cialis use should be avoided if heart conditions preclude sexual activity.
• The medication can have interactions with certain medications like alpha-blockers.
• Men often seek Cialis consultations to improve sexual confidence.
• Treatments like Cialis allow restoration of intimacy in relationships.
• Physician follow-up ensures optimal dosing and safety monitoring.
• Cialis’s approval marked a significant advancement in sexual medicine.
• The drug’s marketing often includes education about ED causes.
• Cialis remains a subject of scientific and clinical interest.

[22] Some sildenafil users see a bluish tinge and have a heightened sensitivity to light because of PDE6 inhibition.

Frequently asked questions

[7] Caution is advised in those with cardiovascular disease. [7] Rare but serious side effects include a prolonged erection that can lead to damage to the penis, vision problems, and hearing loss. [7] Tadalafil is not recommended in people taking nitrovasodilators such as nitroglycerin, as this may result in a serious drop in blood pressure. [7] Tadalafil is a PDE5 inhibitor which increases blood flow to the penis. [7] It also dilates blood vessels in the lungs, which lowers the pulmonary artery pressure.

Dive Insight:

Tadalafil was approved for medical use in the United States in 2003. [7] It is available as a generic medication. [8] In 2022, it was the 172nd most commonly prescribed medication in the United States, with more than 3 million prescriptions. Tadalafil is used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. [7] In the United States, tadalafil (as Cialis) is indicated for the treatment of erectile cialis 20 mg 8 tablets dysfunction and the signs and symptoms of benign prostatic hyperplasia;[4] and (as Adcirca) for the treatment of pulmonary arterial hypertension to improve exercise ability. [22] PDE1 is found in the brain, heart, and vascular smooth muscle. [22] It is thought that the inhibition of PDE1 by sildenafil and vardenafil leads to vasodilation, flushing, and tachycardia. [22] PDE11 is expressed in skeletal muscle, the prostate, the liver, the kidney, the pituitary gland, and the testes.

• The Cialis patent expired in many countries by the mid-2020s.
• Generic tadalafil versions became widely accessible to patients.
• Market competition led to reduced prices for Cialis and generics.
• Lilly continues research on improved formulations of tadalafil.
• Online pharmacies sell Cialis; caution is advised to avoid counterfeits.
• The drug should only be purchased through licensed distributors.
• Awareness campaigns educate about safe use of Cialis.
• Side effect profiles remain similar between brand and generic versions.
• Pharmacovigilance monitors adverse events linked to Cialis use.
• Cialis remains an important option in ED treatment algorithms.
• The medication plays a role in men's sexual health discussions.
• Physicians frequently review Cialis use during follow-up visits.

[22] The effects on the body of inhibiting PDE11 are not known. Tadalafil can be synthesized starting from (D)-tryptophan methyl ester and piperonal via a Pictet–Spengler reaction.

This is followed by condensations with chloroacetyl chloride and methylamine to complete the diketopiperazine ring:[25] The FDA's approval of sildenafil in 1998[26] was a ground-breaking commercial event for the treatment of ED, with sales exceeding US$1 billion.

5 Answers

About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S.

7.1 Potential for Pharmacodynamic Interactions with CIALIS

Our products are available in approx. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion. Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal Click here for our Grünenthal Report 2024/2025 Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia (pdf, 137.3 KB) Tadalafil, sold under the brand name Cialis among others, is a medication used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. [7] Onset is typically within half an hour and the duration is up to 36 hours. Common side effects include headache, muscle pain, flushing, and nausea. Subsequently, the FDA approved both vardenafil[27] and tadalafil in 2003. It initially was developed by the biotechnology company ICOS, and then again developed and marketed worldwide by Lilly ICOS, LLC, the joint venture of ICOS Corporation and Eli Lilly and Company. Tadalafil was approved in 2009 in the United States for the treatment of pulmonary arterial hypertension[28] and is under regulatory review in other regions for this condition. In late November 2008, Eli Lilly sold the exclusive rights to commercialize tadalafil for pulmonary arterial hypertension in the United States to United Therapeutics for an upfront payment of $150 million. Tadalafil was discovered by Glaxo Wellcome (now GlaxoSmithKline) under a partnership between Glaxo and ICOS to develop new drugs that began in August 1991. [29][30] In 1993, the Bothell, Washington, biotechnology company ICOS Corporation began studying compound IC351, a phosphodiesterase type 5 (PDE5) enzyme inhibitor. In 1994, Pfizer scientists discovered that sildenafil, which also inhibits the PDE5 enzyme, caused penile erection in males participating in a clinical study of a heart medicine.

2.6 Use in Specific Populations

[7] The FDA concluded that they were not able to draw a cause and effect relationship, only an association; the label of all three PDE5 inhibitors was changed to alert clinicians to that fact. A 2019 meta-analysis found that tadalafil exposure was not associated with NAION. In October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including tadalafil, requires a more prominent warning of the potential risk of sudden hearing loss as the result of post-marketing reports of deafness associated with use of PDE5 inhibitors. Tadalafil is metabolized predominantly[19] by the liver CYP3A4 enzyme system. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and the smooth muscle of the corpus cavernosum.

8.6 Hepatic Impairment

[medical citation needed] This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cyclic guanosine monophosphate (more commonly known as cyclic GMP or cGMP) in smooth muscle cells. [medical citation needed] cGMP relaxes smooth muscle and increases blood flow to the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by increasing the amount of cGMP. [medical citation needed] Tadalafil (and sildenafil and vardenafil) inhibits PDE5. However, because sexual stimulation is required to initiate the local penile release of nitric oxide, tadalafil's inhibition of PDE5 will have no effect without sexual stimulation. Although ICOS scientists were not testing compound IC351 for treating ED, they recognized its potential usefulness for treating that disorder.

5.7 Renal Impairment

Grünenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men1. The acquisition will expand Grünenthal's Latin American Men's Health product portfolio. "Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal.

2.3 CIALIS for Once Daily Use for Benign Prostatic Hyperplasia

"In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." Through the acquisition of Cialis®, Grünenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Grünenthal has invested over €2 billion in the acquisition of established medicines, including Nebido®, the European rights to Crestor® and Nexium®, as well as the global rights to Vimovo® (excluding the U.S. and Japan), Qutenza® and Zomig® (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. 1 In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men. Soon, in 1994, ICOS received a patent for compound IC351 (structurally unlike sildenafil and vardenafil), and Phase 1 clinical trials began in 1995.

6.1 Clinical Trials Experience

A meta‐analysis found that tadalafil is an effective treatment for lower urinary tract symptoms due to benign prostatic hyperplasia and that such treatment had a low rate of adverse effects. [11] Tadalafil is FDA-approved for males as a therapy to treat and prevent symptoms of benign prostatic hyperplasia, such as urinary urgency, hesitancy, weak stream, dribbling, and incontinence. Tadalafil was found to have similar benefits for lower urinary tract symptoms as the usually prescribed tamsulosin. Tadalafil is approved in the United States, Canada, and Japan to improve exercise ability in people with pulmonary arterial hypertension. The most common potential side effects when using tadalafil are headache, stomach discomfort or pain, indigestion, burping, acid reflux, back pain, myalgia (pain in limbs and extremities), flushing, hypertension (or uncommonly hypotension), and stuffy/runny nose.

5.10 Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4)

[7] Also common are dizziness, peripheral edema, fatigue, and urinary or respiratory tract infection; both diarrhea and constipation have been reported. [7] Diarrhea was reported more frequently in patients 65 or older than in younger subjects. [4] These side effects reflect the ability of PDE5 inhibition to cause vasodilation (causing blood vessels to widen) and usually resolve after a few hours. In May 2005, the US Food and Drug Administration (FDA) found that tadalafil (along with other PDE5 inhibitors) was associated with vision impairment related to NAION (non-arteritic anterior ischemic optic neuropathy). [16] Most, but not all, of these patients, had underlying anatomic or vascular risk factors for the development of NAION, unrelated to PDE5 inhibitor use. In 1997, the Phase 2 clinical studies were initiated for males experiencing ED, then progressed to the Phase 3 trials that supported the drug's FDA approval.